Achaogen grabs $72M from IPO

The antibiotics developer Achaogen raised $72 million from its IPO. The biotech sold 6 million shares at $12 a share, on the low end of its $12 to $14 share. Renaissance Capital reports that the company's insiders--who had said they were willing to buy up to 25% of the shares--did not participate in the offering. Shares of South San Francisco-based Achaogen will trade as AKAO and the biotech emerges with a market cap of $211 million. This year's Q1 biotech IPOs continue to deliver cash to the sector, following up on the big boom of 2013. Story

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.